← Back to Volume 4

Recent Advances of Drug Design Strategies for Classical KRAS Mutations

Xulin Huang
pp.88-93 DOI: 10.62051/yc6p5d86 August 29, 2024
Download PDF
Abstract: KRAS, one of the most common oncogenic mutations, is considered to be a potential target for design of cancer therapies. Previous studies have suggested a poor therapeutic index and lack of efficacy of drugs targeting the KRAS signalling pathway and even leading to think “undrugged”. But recently, major breakthrough in KRAS was achieved in a decade and even up to hit the market which really inspired a lot. This review aims to illustrate the recent advances of drug design strategies for different types of KRAS mutations, including small molecular inhibitors, PROTAC and others.
Keywords: KRAS, mutation, drug design strategies.
APA Citation: Xulin Huang (2024). Recent Advances of Drug Design Strategies for Classical KRAS Mutations. Transactions on Materials, Biotechnology and Life Sciences, 4(1), 88-93. https://doi.org/10.62051/yc6p5d86

References

  1. Martinez P et al 2016 Nat. Commun. 7 12158.
  2. Santos E and Nebreda A R 1989 Faseb J. 3 2151-63
  3. Vetter I R and Wittinghofer A 2001 Science 294 1299-304.
  4. Carvalho Dias P et al 2018 Cancer Res. 78 7-14
  5. Hobbs G A, Der C J and Rossman K L 2016 J. Cell Sci. 129 1287-92
  6. Xie X et al 2023 Signal Transduction and Targeted Therapy 8 335
  7. Huang L et al 2021 Signal Transduction and Targeted Therapy 6 386
  8. FDA Approves First KRAS Inhibitor: Sotorasib 2021Cancer Discovery 11 Of4.
  9. Hallin J et al 2020 Cancer Discovery 10 54-71
  10. Salem M E et al 2022 JCO Precis Oncol. 6 e2100245.
  11. Dong X et al 2024 Cancer Research 84 CT119
  12. Singhal A, Li B T and O’Reilly E M 2024 Nature Medicine 30 969-983
  13. Wang X et al 2022 Journal of Medicinal Chemistry 65 3123-3133
  14. Wei D et al 2024 Clin Cancer Res. 30 655-662
  15. Zhou X, Ji Y and Zhou J. 2023 Molecules 28 3615
  16. Nagashima T et al 2022 European Journal of Cancer 174 S30
  17. Tran T H et al 2020 Proceedings of the National Academy of Sciences of the United States of America 117 3363-3364
  18. Escher T and Satchell K 2023 Molecular Therapy 31 1904-1919
  19. Mao Z et al 2022 Cell Discovery 8 5
  20. Hoffmann M et al 2023 Journal of Clinical Oncology 41 2543
  21. Holderfield M et al 2024 Nature 629 919–926
  22. Mark A M et al 2021 New England Journal of Medicine 384 2382-2393
  23. Xue J Y et al 2020 Nature 577 421-425
  24. Dy G K et al 2023 J Clin Oncol. 41 3311-3317
  25. Yang F et al 2022 European Journal of Medicinal Chemistry 230 114088
  26. Toure M and Crews C M 2016 Angew. Chem. Int. Engl. 55 1966-1973
  27. Burslem G M et al 2018 Cell Chem. Biol. 25 67-77
  28. Zeng M et al 2020 Cell Chemical Biology 27 19-31
  29. Bond M J et al 2020 ACS Central Science 6 1367-1375
  30. Tolcher A W et al 2023 Journal of Clinical Oncology 41 TPS764
  31. Lake D 2016 Cell Mol. Life Sci. 73 4397-4413
  32. Smith K et al 2023 Molecular Cancer Research 21 PR09
  33. Punekar S R et al 2022 Nature Reviews Clinical Oncology 19 637-655
  34. Watanabe T et al 2011 Dis. Colon. Rectum. 54 1170-8
  35. Lee W et al 2018 Scientific Reports 8 11879
  36. Kim W et al 2018 Genome Res. 28 374-82